Abstract：
OBJECTIVE: The primary objective is to systematically review primary studies, such as randomized control trials (RCTs), feasibility, exploratory, and case studies; and the secondary objective is to evaluate all secondary articles, such as reviews, guidelines, and editorials, relevant to the use of StrataXRT for the prevention and/or management of radiation dermatitis (RD) in cancer patients.
METHODS: A literature search was conducted up to February 26, 2023, for articles investigating the use of StrataXRT for the prevention and treatment of RD, in the following databases: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar. The keywords \"StrataXRT\", \"dermatitis\", \"radiotherapy\", and \"radiation\" were used to identify relevant articles.
RESULTS: Twenty-seven articles from 2018 to 2022 were identified to fulfill the inclusion criteria of this review, of which nine are primary studies and 18 are secondary papers. Significant heterogeneity was observed in the current literature studying the effects of StrataXRT, making it difficult to make cross-trial comparisons. There is a suggestion of the efficacy of StrataXRT in the prevention and treatment of RD.
CONCLUSIONS: The findings of this review recommend further adequately powered RCTs with robust methodology including patient and clinician assessments to determine the efficacy of StrataXRT in preventing and treating RD. This is essential to improve the quality of life of patients and identify which groups of patients would benefit most from StrataXRT.
METHODS: A literature search was conducted up to February 26, 2023, for articles investigating the use of StrataXRT for the prevention and treatment of RD, in the following databases: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar. The keywords \"StrataXRT\", \"dermatitis\", \"radiotherapy\", and \"radiation\" were used to identify relevant articles.
RESULTS: Twenty-seven articles from 2018 to 2022 were identified to fulfill the inclusion criteria of this review, of which nine are primary studies and 18 are secondary papers. Significant heterogeneity was observed in the current literature studying the effects of StrataXRT, making it difficult to make cross-trial comparisons. There is a suggestion of the efficacy of StrataXRT in the prevention and treatment of RD.
CONCLUSIONS: The findings of this review recommend further adequately powered RCTs with robust methodology including patient and clinician assessments to determine the efficacy of StrataXRT in preventing and treating RD. This is essential to improve the quality of life of patients and identify which groups of patients would benefit most from StrataXRT.
摘要：
目的：主要目的是系统地回顾主要研究，如随机对照试验(RCT)，可行性,探索性,和案例研究；次要目标是评估所有次要文章，如评论,指导方针,和社论，与使用StrataXRT预防和/或管理癌症患者的放射性皮炎（RD）有关。
方法：直到2023年2月26日，对有关使用StrataXRT预防和治疗RD的文章进行了文献检索。在以下数据库中：OvidMEDLINE,Embase,Cochrane中央对照试验登记册（中央），谷歌学者。关键字\"StrataXRT\",“皮炎”，“放射治疗”，和“辐射”用于识别相关文章。
结果：确定了2018年至2022年的27篇文章，以满足本综述的纳入标准，其中9篇是初级研究，18篇是次级论文。在目前研究StrataXRT效应的文献中观察到显著的异质性，很难进行交叉试验比较。建议StrataXRT在预防和治疗RD中的功效。
结论：本综述的结果推荐了进一步充分有效的随机对照试验，包括患者和临床医生评估，以确定StrataXRT在预防和治疗RD中的功效。这对于改善患者的生活质量和确定哪些患者组将从StrataXRT中受益最重要。
方法：直到2023年2月26日，对有关使用StrataXRT预防和治疗RD的文章进行了文献检索。在以下数据库中：OvidMEDLINE,Embase,Cochrane中央对照试验登记册（中央），谷歌学者。关键字\"StrataXRT\",“皮炎”，“放射治疗”，和“辐射”用于识别相关文章。
结果：确定了2018年至2022年的27篇文章，以满足本综述的纳入标准，其中9篇是初级研究，18篇是次级论文。在目前研究StrataXRT效应的文献中观察到显著的异质性，很难进行交叉试验比较。建议StrataXRT在预防和治疗RD中的功效。
结论：本综述的结果推荐了进一步充分有效的随机对照试验，包括患者和临床医生评估，以确定StrataXRT在预防和治疗RD中的功效。这对于改善患者的生活质量和确定哪些患者组将从StrataXRT中受益最重要。
